Hamid Hoveyda
Corporate Officer/Principal chez Ogeda SA
Provenance du réseau au premier degré de Hamid Hoveyda
Entité | Type d'entité | Industrie | |
---|---|---|---|
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.
14
| Subsidiary | Pharmaceuticals: Major | 14 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Hamid Hoveyda via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Université Catholique de Louvain | College/University | Doctorate Degree Graduate Degree Doctorate Degree | |
Université Libre de Bruxelles | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree | |
Ncardia SA
Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Epics Therapeutics SA
Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Miscellaneous Commercial Services | Founder Founder Chairman | |
Q-Biologicals NV
Q-Biologicals NV BiotechnologyHealth Technology Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree | |
TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member | |
Novadip Biosciences SA
Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Biotechnology | Director/Board Member Director/Board Member | |
MaSTherCell SA
MaSTherCell SA BiotechnologyHealth Technology MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | Investment Managers | Private Equity Investor Private Equity Investor | |
Bioxodes SA
Bioxodes SA Pharmaceuticals: MajorHealth Technology Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman | |
CropDesign NV
CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director of Finance/CFO Director/Board Member | |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
ACTICOR BIOTECH SAS | Biotechnology | Director/Board Member | |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member | |
Vesalius Biocapital Partners SARL
Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg. | Investment Managers | Private Equity Investor | |
VOLUNTIS S.A. | Packaged Software | Director/Board Member | |
Thémis SA | Director/Board Member | ||
Newton Biocapital Partners SRL
Newton Biocapital Partners SRL Investment ManagersFinance Newton Biocapital Partners SPRL is an Independent Venture Capital firm founded in 2017 by Alain Parthoens. Newton Biocapital Partners SPRL is headquartered in Woluwe-Saint-Pierre. | Investment Managers | Founder | |
Vesalius Biocapital II Partners SARL | Founder | ||
Bio-Sourcing SA
Bio-Sourcing SA BiotechnologyHealth Technology Bio-Sourcing SA develops and markets biological drugs for veterinary use. The firm focuses on farm animal health and companion animal health. The company was founded by Bertrand Mérot in June 2011 and is headquartered in Liege, Belgium. | Biotechnology | Director/Board Member | |
Solvay Business School of Economics & Management | College/University | Undergraduate Degree | |
AQ Invest BV | Corporate Officer/Principal | ||
AQ Partners SRL | Corporate Officer/Principal | ||
A Q Invest SRL | Corporate Officer/Principal | ||
Ncardia Holding SA
Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | Biotechnology | Director/Board Member | |
ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal | |
Northwestern University
Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | College/University | Doctorate Degree | |
EUROFIMA European Co for Financing of Railroad Rolling Stock
EUROFIMA European Co for Financing of Railroad Rolling Stock SupranationalGovernment EUROFIMA European Company for the Financing of Railroad Rolling Stock engages in the business of providing finance services to railway equipment through borrowings and equity capital. The company's services encompass joint purchases, funding and lending. It also finances the acquisition and modernization of railway equipment. The company was founded on November 20, 1956 and is headquartered in Basel, Switzerland. | Supranational | Director/Board Member | |
Telenet BV
Telenet BV Cable/Satellite TVConsumer Services Telenet NV provides telephone, television and internet services. It offers internet, television, telephone, mobile phone, entertainment services. The company was founded in October 1994 and is headquartered in Mechelen, Belgium. | Cable/Satellite TV | Director/Board Member | |
D'IETEREN GROUP | Other Consumer Services | Director/Board Member | |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Miscellaneous Commercial Services | Director/Board Member | |
EUROPEAN MEDICAL SOLUTIONS | Biotechnology | Director/Board Member | |
Tibotec Virco NV
Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
SOS Villages d'Enfants Belgique | Director/Board Member | ||
ACKERMANS & VAN HAAREN NV | Engineering & Construction | Chief Executive Officer | |
Van Laere Group
Van Laere Group Engineering & ConstructionIndustrial Services Part of Ackermans & van Haaren NV, Van Laere Group operates as a general contractor. The company is based in Zwijndrecht, Belgium. The Belgian company was founded in 1938. The CEO is Manu Coppens. | Engineering & Construction | Director/Board Member | |
Brinvest NV
Brinvest NV MiscellaneousMiscellaneous Founded in 1987, Brinvest NV is a holding company that is based in Antwerp, Belgium. The Belgian company's description states that it is involved in offices of holding companies not elsewhere classified. | Miscellaneous | Director/Board Member | |
BPI Real Estate Luxembourg SARL
BPI Real Estate Luxembourg SARL Real Estate DevelopmentFinance Part of Ackermans & van Haaren NV, BPI Real Estate Luxembourg SARL is a major player in real estate development for over 30 years, both in the Belgian and international market. The company is based in Luxembourg, Luxembourg. The Luxembourger company designs and develops innovative real estate projects that focus on sustainability and meet the needs of their clients. BPI Urban Shapers is their approach to real estate development. The CEO of the company is Arnaud Regout. | Real Estate Development | Director/Board Member | |
Mobix Stevens NV
Mobix Stevens NV Engineering & ConstructionIndustrial Services Founded in 1969, Mobix Stevens NV is a subsidiary of Ackermans & van Haaren NV. The company is based in Halen, Belgium. The Belgian company constructs electricity and telecommunications line projects. | Engineering & Construction | Director/Board Member | |
BPC Group NV | Director/Board Member | ||
Mobix Engema NV
Mobix Engema NV Engineering & ConstructionIndustrial Services Part of Ackermans & van Haaren NV, Mobix Engema NV is a Belgian company that provides innovative and smart total solutions for railway and infrastructure projects. The company is based in Mechelen, Belgium. The company's rail division offers expertise in overhead lines, signaling, and railway construction, while its utilities division specializes in public lighting, data network installation for telecommunications and security, and the construction of distribution networks for gas and electricity. The company was founded in 1935. Eeraerts Laurent has been the CEO of the company since 2018. | Engineering & Construction | Director/Board Member | |
HDP Charleroi NV | Director/Board Member | ||
DEME GROUP NV | Engineering & Construction | Director/Board Member | |
Brussels Airport Co. SA
Brussels Airport Co. SA Other TransportationTransportation Brussels Airport Co. SA operates and manages brussels airport. It offers flight information, timetable, special assistance, security and baggage and travel information for passenger. The firm’s business to business include aviation marketing, commercial partners, travel agents and tour operators and advertising at the airport. The company was founded in 1914 and is headquartered in Brussels, Belgium. | Other Transportation | Director of Finance/CFO |
Statistiques
Internationale
Belgique | 38 |
Luxembourg | 5 |
France | 4 |
Pays-Bas | 3 |
Etats-Unis | 3 |
Sectorielle
Health Technology | 17 |
Consumer Services | 8 |
Commercial Services | 6 |
Industrial Services | 6 |
Finance | 5 |
Opérationnelle
Director/Board Member | 177 |
Corporate Officer/Principal | 20 |
Independent Dir/Board Member | 18 |
Chairman | 11 |
Chief Executive Officer | 9 |
Relations les plus connectées
Insiders | |
---|---|
Piet Dejonghe | 58 |
Chris Buyse | 39 |
Jean-Paul Prieels | 32 |
Alain Parthoens | 29 |
Michel Allé | 20 |
Raf Moons | 15 |
Philippe Monteyne | 10 |
Yves Joseph Ribeill | 9 |
Jean Combalbert | 8 |
Philippe Degive | 8 |
Graeme Fraser | 5 |
Al Gray | 4 |
Vincent Lannoy | 2 |
Steven Ramael | 1 |
- Bourse
- Insiders
- Hamid Hoveyda
- Connexions Sociétés